Expert perspectives

Hear the perspectives of biosimilar experts around the world

Video
Dr Richard Adams, Clinical Oncologist, Cardiff University, Wales, explains the importance of engaging patients in biosimilars trials.
Watch Now
Video
Professor Ernest Choy, Head of Rheumatology and Translational Research, Cardiff University, Wales, explores the use of biosimilars in other approved indications.
Watch Now
Video
Dr Richard Adams, Clinical Oncologist, Cardiff University, Wales, gives an overview of the use of biosimilars in oncology care.
Watch Now
Video
Professor Ernest Choy, Head of Rheumatology and Translational Research, Cardiff University, Wales, discusses the use of biosimilars in rheumatoid arthritis.
Watch Now
Video
Gillian Woollett, Vice President at Avalere Health, discusses the importance of biosimilars and how they influence access to care.
Watch Now
Video
Peter Pitts, President of the Center of Medicine in the Public Interest, discusses the importance of biosimilars and how they influence innovation and regulation.
Watch Now
Video
Gillian Woollet, Vice President at Avalere Health, explores why the field is an interesting area with great opportunity for growth.
Watch Now
Video
John Doyle, Senior VP & Managing Director of Global Market Access Consulting at Quintiles, discusses the importance of biosimilars and how they influence market access.
Watch Now
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, notes that all patients, regardless of what arm of the clinical trial they are in, will receive the active product and John Doyle, Senior VP & Managing Director of Global Market Access Consulting, Quintiles, describes how patients will gain the ability to have their opinions heard on the outcomes of research.
Watch Now
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy at Quintiles, explains why the clinical research and regulation of biosimilar medicines is far more rigorous than for small-molecule generic drugs.
Watch Now
Video
Kamali Chance, Head of Global Biosimilars Regulatory Strategy, Quintiles explains why sites should get involved in clinical trials for biosimilars.
Watch Now